Advertisement
Journal of Investigative Dermatology Home

A Multicenter Phase II Study of Pazopanib in Patients with Unresectable Dermatofibrosarcoma Protuberans

Published:September 18, 2020DOI:https://doi.org/10.1016/j.jid.2020.06.039
      Dermatofibrosarcoma protuberans (DFSP) is a soft-tissue sarcoma characterized by a high risk of local infiltration. The identification of the COL1A1-PDGFB t(17;22) translocation activating the PDGF pathway led to the use of imatinib in unresectable DFSP, with a response rate of 36–80%. Pazopanib is a multitarget tyrosine kinase inhibitor approved for soft-tissue sarcomas. We conducted a phase II study of patients with unresectable DFSP to evaluate the efficacy and safety of pazopanib. Patients received 800 mg of pazopanib daily. The primary endpoint was the objective response rate defined as the reduction of the largest diameter of the tumor by ≥30% at 6 months or at surgery. A total of 23 patients, including one pretreated with imatinib, were enrolled. With a median follow-up of 6.2 months (interquartile range = 5.6–7.8 months), five patients (22%, 95% confidence interval = 7–22%) had a partial response to pazopanib. The best objective response rate was 30% (95% confidence interval = 13–53%) using Response Evaluation Criteria in Solid Tumors. One patient with metastatic DFSP previously treated with imatinib died after 2.4 months. Nine patients (39%) discontinued the treatment owing to adverse events. Pharmacodynamics analyses of tumor samples were conducted: the enrichment of EGF and the EGFR-associated gene panel was associated with resistance, suggesting that EGFR-targeted therapies could be a therapeutic option to explore in DFSP.

      Trial registration

      ClinicalTrials.gov identifier: NCT01059656.

      Abbreviations:

      DFSP (dermatofibrosarcoma protuberans), PDGFR (PDGF receptor), PR (partial response), RECIST (Response Evaluation Criteria in Solid Tumors), SDx (stable disease), sVEGFR-2 (soluble VEGF receptor-2), VEGFR (VEGF receptor)
      To read this article in full you will need to make a payment
      Purchase one-time access
      Society Members (SID/ESDR), remember to log in for access.
      Subscribe to Journal of Investigative Dermatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • A’Hern R.P.
        Sample size tables for exact single-stage phase II designs.
        Stat Med. 2001; 20: 859-866
        • Baird K.
        • Davis S.
        • Antonescu C.R.
        • Harper U.L.
        • Walker R.L.
        • Chen Y.
        • et al.
        Gene expression profiling of human sarcomas: insights into sarcoma biology.
        Cancer Res. 2005; 65: 9226-9235
        • Benjamini Y.
        • Hochberg Y.
        Controlling the false discovery rate: a practical and powerful approach to multiple testing.
        J R Stat Soc Series B (Methodol). 1995; 57: 289-300
        • Beuselinck B.
        • Jean-Baptiste J.
        • Schöffski P.
        • Couchy G.
        • Meiller C.
        • Rolland F.
        • et al.
        Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinib.
        BJU Int. 2016; 118: 890-901
        • Chao C.
        • Al-Saleem T.
        • Brooks J.J.
        • Rogatko A.
        • Kraybill W.G.
        • Eisenberg B.
        Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade.
        Ann Surg Oncol. 2001; 8: 260-267
        • Dadone-Montaudié B.
        • Alberti L.
        • Duc A.
        • Delespaul L.
        • Lesluyes T.
        • Pérot G.
        • et al.
        Alternative PDGFD rearrangements in dermatofibrosarcomas protuberans without PDGFB fusions.
        Mod Pathol. 2018; 31: 1683-1693
        • Eilers G.
        • Czaplinski J.T.
        • Mayeda M.
        • Bahri N.
        • Tao D.
        • Zhu M.
        • et al.
        CDKN2A/p16 loss implicates CDK4 as a therapeutic target in imatinib-resistant dermatofibrosarcoma protuberans.
        Mol Cancer Ther. 2015; 14: 1346-1353
        • Eisenhauer E.A.
        • Therasse P.
        • Bogaerts J.
        • Schwartz L.H.
        • Sargent D.
        • Ford R.
        • et al.
        New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
        Eur J Cancer. 2009; 45: 228-247
        • Fiore M.
        • Miceli R.
        • Mussi C.
        • Lo Vullo S.
        • Mariani L.
        • Lozza L.
        • et al.
        Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate.
        J Clin Oncol. 2005; 23: 7669-7675
        • Fu Y.
        • Kang H.
        • Zhao H.
        • Hu J.
        • Zhang H.
        • Li X.
        • et al.
        Sunitinib for patients with locally advanced or distantly metastatic dermatofibrosarcoma protuberans but resistant to imatinib.
        Int J Clin Exp Med. 2015; 8: 8288-8294
        • Giacchero D.
        • Maire G.
        • Nuin P.A.
        • Berthier F.
        • Ebran N.
        • Carlotti A.
        • et al.
        No correlation between the molecular subtype of COL1A1–PDGFB fusion gene and the clinico-histopathological features of dermatofibrosarcoma protuberans.
        J Invest Dermatol. 2010; 130: 904-907
        • Glade Bender J.L.
        • Lee A.
        • Reid J.M.
        • Baruchel S.
        • Roberts T.
        • Voss S.D.
        • et al.
        Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children’s oncology group phase I consortium report.
        J Clin Oncol. 2013; 31: 3034-3043
        • Greco A.
        • Fusetti L.
        • Villa R.
        • Sozzi G.
        • Minoletti F.
        • Mauri P.
        • et al.
        Transforming activity of the chimeric sequence formed by the fusion of collagen gene COL1A1 and the platelet derived growth factor b-chain gene in dermatofibrosarcoma protuberans.
        Oncogene. 1998; 17: 1313-1319
        • Iyoda A.
        • Hiroshima K.
        • Baba M.
        • Fujisawa T.
        • Yusa T.
        • Ohwada H.
        Expression of vascular endothelial growth factor in thoracic sarcomas.
        Ann Thorac Surg. 2001; 71: 1635-1639
        • Kamar F.G.
        • Kairouz V.F.
        • Sabri A.N.
        Dermatofibrosarcoma protuberans (DFSP) successfully treated with sorafenib: case report.
        Clin Sarcoma Res. 2013; 3: 5
        • Kérob D.
        • Porcher R.
        • Vérola O.
        • Dalle S.
        • Maubec E.
        • Aubin F.
        • et al.
        Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients.
        Clin Cancer Res. 2010; 16: 3288-3295
        • Liang C.A.
        • Jambusaria-Pahlajani A.
        • Karia P.S.
        • Elenitsas R.
        • Zhang P.D.
        • Schmults C.D.
        A systematic review of outcome data for dermatofibrosarcoma protuberans with and without fibrosarcomatous change.
        J Am Acad Dermatol. 2014; 71: 781-786
        • Llovet J.M.
        • Peña C.E.A.
        • Lathia C.D.
        • Shan M.
        • Meinhardt G.
        • Bruix J.
        • et al.
        Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.
        Clin Cancer Res. 2012; 18: 2290-2300
        • Maitland M.L.
        • Xu C.F.
        • Cheng Y.C.
        • Kistner-Griffin E.
        • Ryan K.A.
        • Karrison T.G.
        • et al.
        Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of Pazopanib.
        Clin Cancer Res. 2015; 21: 365-372
        • Martin-Broto J.
        • Stacchiotti S.
        • Lopez-Pousa A.
        • Redondo A.
        • Bernabeu D.
        • de Alava E.
        • et al.
        Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.
        Lancet Oncol. 2019; 20: 134-144
        • McArthur G.A.
        • Demetri G.D.
        • van Oosterom A.
        • Heinrich M.C.
        • Debiec-Rychter M.
        • Corless C.L.
        • et al.
        Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.
        J Clin Oncol. 2005; 23: 866-873
        • Mir O.
        • Cropet C.
        • Toulmonde M.
        • Cesne A.L.
        • Molimard M.
        • Bompas E.
        • et al.
        Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.
        Lancet Oncol. 2016; 17: 632-641
        • Miyagawa T.
        • Kadono T.
        • Kimura T.
        • Saigusa R.
        • Yoshizaki A.
        • Miyagaki T.
        • et al.
        Pazopanib induced a partial response in a patient with metastatic fibrosarcomatous dermatofibrosarcoma protuberans without genetic translocations resistant to mesna, doxorubicin, ifosfamide and dacarbazine chemotherapy and gemcitabine-docetaxel chemotherapy.
        J Dermatol. 2017; 44: e21-e22
        • Navarrete-Dechent C.
        • Mori S.
        • Barker C.A.
        • Dickson M.A.
        • Nehal K.S.
        Imatinib treatment for locally advanced or metastatic dermatofibrosarcoma protuberans: a systematic review.
        JAMA Dermatol. 2019; 155: 361-369
        • Osio A.
        • Xu S.
        • El Bouchtaoui M.
        • Leboeuf C.
        • Gapihan G.
        • Lemaignan C.
        • et al.
        EGFR is involved in dermatofibrosarcoma protuberans progression to high grade sarcoma.
        Oncotarget. 2018; 9: 8478-8488
        • Park S.
        • Cho S.
        • Kim M.
        • Park J.U.
        • Jeong E.C.
        • Choi E.
        • et al.
        Dermatofibrosarcoma protuberans: a retrospective study of clinicopathological features and related Akt/mTOR, STAT3, ERK, cyclin D1, and PD-L1 expression.
        J Am Acad Dermatol. 2018; 79: 843-852
        • Peña C.
        • Lathia C.
        • Shan M.
        • Escudier B.
        • Bukowski R.M.
        Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial.
        Clin Cancer Res. 2010; 16: 4853-4863
        • Rutkowski P.
        • Klimczak A.
        • Ługowska I.
        • Jagielska B.
        • Wągrodzki M.
        • Dębiec-Rychter M.
        • et al.
        Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate - the impact of fibrosarcomatous transformation.
        Eur J Surg Oncol. 2017; 43: 1134-1141
        • Rutkowski P.
        • Van Glabbeke M.
        • Rankin C.J.
        • Ruka W.
        • Rubin B.P.
        • Debiec-Rychter M.
        • et al.
        Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.
        J Clin Oncol. 2010; 28: 1772-1779
        • Samuels B.L.
        • Chawla S.P.
        • Somaiah N.
        • Staddon A.P.
        • Skubitz K.M.
        • Milhem M.M.
        • et al.
        Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma.
        Cancer. 2017; 123: 4640-4647
        • Simon M.P.
        • Pedeutour F.
        • Sirvent N.
        • Grosgeorge J.
        • Minoletti F.
        • Coindre J.M.
        • et al.
        Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma.
        Nat Genet. 1997; 15: 95-98
        • Siref A.
        • Patel V.
        • Reith J.D.
        • Balzer B.L.
        • Shon W.
        Evaluation of p16 protein expression and CDKN2A deletion in conventional and fibrosarcomatous dermatofibrosarcoma protuberans.
        Pathology. 2018; 50: 474-475
        • Sleijfer S.
        • Ray-Coquard I.
        • Papai Z.
        • Le Cesne A.
        • Scurr M.
        • Schöffski P.
        • et al.
        Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer-soft tissue and bone sarcoma group (EORTC study 62043).
        J Clin Oncol. 2009; 27: 3126-3132
        • Sloan B.
        • Scheinfeld N.S.
        Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy.
        Curr Opin Investig Drugs. 2008; 9: 1324-1335
        • Stacchiotti S.
        • Astolfi A.
        • Gronchi A.
        • Fontana A.
        • Pantaleo M.A.
        • Negri T.
        • et al.
        Evolution of dermatofibrosarcoma protuberans to DFSP-derived fibrosarcoma: an event marked by epithelial-mesenchymal transition-like process and 22q loss.
        Mol Cancer Res. 2016; 14: 820-829
        • Stacchiotti S.
        • Pantaleo M.A.
        • Negri T.
        • Astolfi A.
        • Tazzari M.
        • Dagrada G.P.
        • et al.
        Efficacy and biological activity of imatinib in metastatic dermatofibrosarcoma protuberans (DFSP).
        Clin Cancer Res. 2016; 22: 837-846
        • Subramanian A.
        • Tamayo P.
        • Mootha V.K.
        • Mukherjee S.
        • Ebert B.L.
        • Gillette M.A.
        • et al.
        Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.
        Proc Natl Acad Sci USA. 2005; 102: 15545-15550
        • Ugurel S.
        • Mentzel T.
        • Utikal J.
        • Helmbold P.
        • Mohr P.
        • Pföhler C.
        • et al.
        Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up.
        Clin Cancer Res. 2014; 20: 499-510
        • van der Graaf W.T.
        • Blay J.Y.
        • Chawla S.P.
        • Kim D.W.
        • Bui-Nguyen B.
        • Casali P.G.
        • et al.
        Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.
        Lancet. 2012; 379: 1879-1886
        • World Health Organization
        WHO handbook for reporting results of cancer treatment.
        (accessed 6 October 2020)